晚发型婴儿Krabbe病造血干细胞移植的长期神经发育结局
这项前瞻性纵向研究评估了19例晚发型婴儿Krabbe病(6-36月龄)患者接受造血干细胞移植的疗效。与未治疗患者相比,移植受者生存概率更长,认知和语言功能改善。无症状患者获益最大,所有领域发育正常或接近正常。
要点
- 移植延长晚发型婴儿Krabbe病患者生存期并改善功能能力
- 无症状时移植获益最大,所有领域发育正常或接近正常
- 症状 onset ≤12月龄者认知结局与未治疗患者相当
核心结论
- HSCT延长晚发型婴儿Krabbe病患者寿命并改善功能能力,尤其在症状出现前移植者获益最大
- 研究结果支持将晚发型婴儿Krabbe病重新定义为症状 onset 12至36月龄
研究设计与样本
- 前瞻性纵向研究,单中心标准化方案评估
- 19例晚发型婴儿Krabbe病患者于1997年3月至2020年1月接受HSCT
- 采用Kaplan-Meier法进行生存分析,混合回归模型估计组间差异
主要发现
- 与未治疗患者相比,移植受者生存概率更长,认知和语言功能改善
- 粗大和精细运动发育受影响最大,结果不一
- 无症状患者移植后所有领域发育正常或接近正常,仅部分粗大运动延迟
- 症状 onset >12月龄的有症状患者认知结局优于未治疗患者
- 症状 onset ≤12月龄的有症状患者认知结局与未治疗患者相当
临床怎么用
- 晚发型婴儿Krabbe病患者应考虑HSCT,尤其应在症状出现前进行移植
- 症状 onset ≤12月龄的患者移植认知获益有限,需个体化评估
局限性
- 单中心研究,样本量19例
- 粗大和精细运动发育结果可变
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Krabbe disease is a rare neurodegenerative disorder caused by a deficiency in galactocerebrosidase. The only effective treatment is hematopoietic stem cell transplantation (HSCT). Approximately 85% of Krabbe disease cases are the infantile subtypes, among which ∼20% are late infantile. Prior studies have demonstrated that HSCT is effective for early-infantile patients (0-6 months of age) who undergo transplantation while asymptomatic, compared with those receiving transplants while symptomatic. However, no studies evaluated the efficacy of HSCT for late-infantile patients (6-36 months). In this prospective, longitudinal study, patients were evaluated at a single site according to a standardized protocol. Survival analysis was performed using the Kaplan-Meier method. Differences between groups were estimated using mixed regression models to account for within-person repeated measures. Nineteen late-infantile patients underwent HSCT (March 1997 to January 2020). Compared with untreated patients, transplant recipients had a longer survival probability and improved cognitive and language function. Gross and fine motor development were most affected, with variable results. Asymptomatic patients benefitted the most from transplantation, with normal to near-normal development in all domains and some gross motor delays. Among symptomatic patients, those with disease onset at >12 months of age had better cognitive outcomes than untreated patients. Those with disease onset at ≤12 months were comparable to untreated patients. We found that HSCT prolonged the lifespan and improved the functional abilities of late-infantile patients with Krabbe disease, particularly those who underwent transplantation before onset of symptoms. In addition, our findings support prior literature that reclassifies late-infantile Krabbe disease to be symptom onset at 12 to 36 months of age.
引用
- Yoon IC, Bascou NA, Poe MD, et al. Long-term neurodevelopmental outcomes of hematopoietic stem cell transplantation for late-infantile Krabbe disease. Blood. 2021. PMID: 33150395. doi:10.1182/blood.2020005477
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。